Compare GPCR & GBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GPCR | GBDC |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Finance: Consumer Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.4B |
| IPO Year | 2023 | 2009 |
| Metric | GPCR | GBDC |
|---|---|---|
| Price | $49.09 | $13.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $103.17 | $14.38 |
| AVG Volume (30 Days) | 534.2K | ★ 1.1M |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 11.69% |
| EPS Growth | N/A | ★ 4.41 |
| EPS | N/A | ★ 0.29 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $45.55 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.26 | $11.77 |
| 52 Week High | $94.90 | $14.93 |
| Indicator | GPCR | GBDC |
|---|---|---|
| Relative Strength Index (RSI) | 45.68 | 53.43 |
| Support Level | $43.76 | $12.70 |
| Resistance Level | $52.60 | $13.45 |
| Average True Range (ATR) | 2.52 | 0.22 |
| MACD | -0.29 | 0.00 |
| Stochastic Oscillator | 22.33 | 60.97 |
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
Golub Capital BDC Inc. is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in U.S. middle-market companies. It also invests in second-lien and subordinated loans, warrants, and minority equity securities in U.S. middle-market companies. The company generally invests in securities rated below investment grade by independent rating agencies, or those that would be rated below investment grade if evaluated. The company operates in the USA, Canada, and other countries, with the majority of its revenue coming from the USA.